Pfizer Settles Foreign Bribery Charges With Prosecution Deferred
This article was originally published in The Tan Sheet
Executive Summary
Pfizer settles with DoJ and SEC to resolve charges its subsidiaries bribed foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ. In a separate case, Pfizer’s Wyeth subsidiary agrees to pay $18.9 million in disgorgement of net profits and prejudgment interest to SEC.
You may also be interested in...
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.
DoJ Bull’s Eye: Off-Label Promotion, Formulary Placements, FCPA Violations Remain Targets
A Pfizer attorney says government saber rattling over individual liability does not mean there will be a spike in individual prosecutions; Pfizer’s cooperation with the government helped it avoid criminal resolution in a Foreign Corrupt Practices Act settlement.
J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
The government charged J&J with bribing doctors in Greece, Poland and Romania to order or prescribe its products; the $70 million settlement includes a deferred prosecution agreement.